Time to Improve Bortezomib and Lenalidomide Lines of Therapy
Stéphanie Guidez(Inserm), Hélène Demarquette(Ikerbasque), Cristina João(Universidade Nova de Lisboa), Thierry Façon(Université de Lille), Laurent Garderet(Inserm), Katell Le Dû(Clinique Victor Hugo), Evangelos Terpos(National and Kapodistrian University of Athens), Lionel Karlin(Hôpital Lyon Sud), Charles Lancesseur(Centre Hospitalier Universitaire de Caen Normandie), Brigitte Pegourié(Centre Hospitalier Universitaire de Grenoble), Niels Abildgaard(University of Southern Denmark), Valentine Richez(Centre Hospitalier Universitaire de Nice), Margaret Macro(Hôpital Cochin), Denis Caillot, Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Sonja Zweegman(Vrije Universiteit Amsterdam), Souhila Ikhlef(Sorbonne Université), Cyrille Hulin(Hôpital Cardiologique du Haut-Lévêque), Marie Lorraine Chrétien(CHU Dijon Bourgogne), Anne‐Marie Stoppa(Institut Paoli-Calmettes), Lofti Benboubker(Centre Hospitalier Universitaire de Tours), Éric Voog(Centre Jean Bernard), Anne Banos(Centre Hospitalier de la Côte Basque)
University of Southern Denmark Research Portal (University of Southern Denmark)
January 1, 2017
Cited by 0
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906